PFE

Pfizer, Inc.

52.43
USD
2.93%
52.43
USD
2.93%
38.93 61.71
52 weeks
52 weeks

Mkt Cap 292.46B

Shares Out 5.58B

Chat
Send me real-time posts from this site at my email

mRNA vaccines superior to others in COVID variant antibody response, study finds

The cohort study, published in PLoS Medicine, included 165 health care workers in the Netherlands vaccinated with one of the two mRNA shots, or those from AstraZeneca (NASDAQ:AZN) or Johnson & Johnson. Four weeks after completing the initial vaccination series, neutralizing antibody titers were highest in those who received the Moderna (MRNA) vaccine, followed by those who got the Pfizer (PFE)/BioNTech (BNTX) shot. The effectiveness of the non-mRNA vaccines was substantially lower. Results also showed that after receiving a Pfizer (PFE)/BioNTech (BNTX) booster, antibodies increased against all variants, including Omicron. However, neutralization titers were lower in those who didn't receive a mRNA shot initially. Check out how Seeking Alpha contributor The Value Investor views Moderna (MRNA) after its recent quarterly earnings.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue